Ask AI
ProCE Banner Activity

Targeting the Future of Pancreatic Cancer Care: RAS, Biomarkers, and Emerging Therapies

Podcast

With updates from the 2026 ASCO Annual Conference signaling long-awaited progress in pancreatic cancer, expert faculty review and discuss recent advances that may influence therapeutic decision-making in a historically chemotherapy-centered field. They examine the current role and limitations of multiagent chemotherapy, the growing importance of early germline and somatic testing, and emerging data for RAS-targeted therapies, including pan-RAS inhibition and allele-specific approaches. Faculty also discuss how molecular subsets such as KRAS wild-type disease, NRG1 fusions, CLDN18.2 expression, MTAP loss, and other actionable alterations may shape future treatment selection, sequencing, clinical trial enrollment, and supportive care planning for patients with pancreatic cancer.

Released: July 22, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education, in partnership with the Pancreatic Cancer Action Network (PanCAN)

ProCE Banner

Supporters

Supported by educational grants from Novocure and Revolution Medicines, Inc.

Novocure

Revolution Medicines, Inc.

Partners

Pancreatic Cancer Action Network (PanCAN)

ProCE Banner

Target Audience

This activity is designed for community oncologists, advanced practice providers, oncology nurses, pharmacists, and other healthcare professionals involved in the multidisciplinary care of patients with pancreatic cancer across all disease stages, aiming to improve frontline and later-line treatment outcomes.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess emerging biomarker and molecular profiling data to guide personalized treatment decisions that incorporate novel therapeutic modalities

  • Select frontline and subsequent therapies for pancreatic cancer using current clinical evidence and guideline-based criteria, tailored to disease stage, patient performance status, and molecular biomarker profiles

  • Implement practical dose modification, toxicity monitoring, and supportive care strategies to manage gastrointestinal, hematologic, and neuropathic adverse events associated with pancreatic cancer therapies

Financial Disclosures

Primary Author

Efrat Dotan, MD, MTR: consultant/advisor/speaker: AbbVie, Amgen, Jazz, Lutris, Merck, Merus; researcher: AstraZeneca, Bristol Myers Squibb, Ipsen.

Andrew H. Ko, MD, FASCO: researcher: Apexigen, Arcus, Astellas, Bristol Myers Squibb, Crystal Genomic, Leap Therapeutics, Novartis, Revolution Medicines, Roche/Genentech, Verastem; consultant/advisor/speaker: Astellas, Corcept, Gilead, Jazz, Legend Biotech, Merus, Pfizer, Renovo, Revolution Medicines, Tango Therapeutics.

Paul E. Oberstein, MD, MS: consultant/advisor/speaker: Ipsen, Lilly, Revolution Medicine, Tango Therapeutics.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.